Evestra Snags DoD Grant For Experimental Breast Cancer Drug Research

By David Holley, Xconomy San Antonio—A small Texas biotech that develops women’s health ...

Promising Treatment for Ebola Virus to be Tested at Texas Biomed

Ricardo Carrion, Jr., Ph.D. During the West African Ebola outbreak that began in 2013, an experimental ...

Former KCI executive to lead new San Antonio biotech company
September 12, 2016

Photo Courtesy of Atteris

Atteris Healthcare LLC, a San Antonio-based wound-care company, has hired Chris Fashek to be its new CEO.

Fashek has strong ties to the Alamo City and its bioscience industry. He previously was president and vice chairman of KCI USA, a San Antonio-based medical technology company that's carved out significant business in the wound-care arena and has since rebranded as Acelity LP. He also was chairman of Systagenix, one of KCI's sister companies.

In his new role, Fashek will play a critical role in Atteris' roll out of advanced wound- and skin-healing products. Atteris was created this year by Rochal Industries LLC and The Catalyst Group Inc.

Rochal Industries is a research and development company focused on creating technologies that improve outcomes for patients with chronic, hard-to-heal wounds. Fashek will also be vice chairman of that company, which, like Atteris, has its headquarters in San Antonio.

Ron Nixon, founder of the Catalyst Group and chairman of Atteris, said Fashek brings critical experience to the young company.

"Throughout his career, he has successfully delivered proven wound-care technologies to providers and patients," Nixon said in a news release. "With his leadership and with the collaboration of Atteris and Rochal Industries, we expect to bring many proprietary innovations to the global market in the near term."

W. Scott Bailey - Reporter/Project Coordinator, San Antonio Business Journal

Stay informed. Subscribe to BioMed SA news alerts.